Lixte Biotechnology Holdings, Inc., including its subsidiary, Lixte Biotechnology, Inc., is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company's primary focus is developing new treatments for human cancers. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. This approach has led to the development of over two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have use in the prevention and treatment of neurodegenerative diseases.
Branches Of Biology Cancer Health Sciences Treatment Of Cancer Drug Discovery Pharmaceutical Sciences Antineoplastic Drugs Neurodegenerative Diseases Histone Deacetylase